Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Oramed Pharmaceuticals (ORMP) has shared an update.
Oramed Pharmaceuticals Inc. has initiated an agreement with Rodman & Renshaw LLC and StockBlock Securities LLC to sell shares of its common stock up to $75 million in “at the market” offerings. This flexible sales strategy enables the company to sell shares through the agents, directly on The Nasdaq Capital Market, or in other ways permitted by law. The agents will earn a commission of up to 3% on sales, and the company may terminate the agreement with a five-day notice. Concurrently, Oramed terminated its previous agreement with Cantor Fitzgerald, through which it had already raised approximately $26.25 million.
See more data about ORMP stock on TipRanks’ Stock Analysis page.
